rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    PYPD
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      A $1.65 Billion Buyout Deal Puts a Spotlight on PolyPid Ahead of Its FDA Decision (NASDAQ: PYPD)
      Nov 16BenzingaPYPD
      PolyPid: 3 Key Takeaways for Long-Term Investors
      Nov 11Yahoo FinancePYPD
      PolyPid Ltd. Q3 2026 Earnings Call Summary
      Nov 11Yahoo FinancePYPD
      PolyPid Ltd (PYPD) Q3 2026 Earnings Call Highlights: D-PLEX100 Nears FDA Decision as Azurity ...

      PolyPid Ltd (PYPD) heads into a November 28, 2026 PDUFA date with labeling talks underway, a $30 million Azurity partnership already paying off, and cash runway into 2028.

      Nov 11Yahoo FinancePYPD
      What PolyPid (PYPD) Said on Its Q3 Earnings Call
      Nov 11Yahoo FinancePYPD
      Earnings call transcript: PolyPid narrows Q3 2026 loss as FDA decision nears
      Nov 11Investing.comPYPD
      PolyPid Q3 2026 Earnings Call Transcript
      Nov 11BenzingaPYPD
      PolyPid Provides Corporate Update and Reports Third Quarter 2026 Financial Results
      Nov 11Yahoo FinancePYPD
      PolyPid Nears a Potentially Transformative FDA Decision as It Advances Its Innovative Pipeline (NASDAQ: P
      Nov 10BenzingaPYPD
      PolyPid: Strong Phase 3 Data Support A Buy Ahead Of November's FDA Decision (NASDAQ:PYPD)

      PolyPid's SHIELD II Phase 3 data showed clinically meaningful reductions in surgical site infections. Read why I rate PYPD stock a Buy.

      Nov 4Seeking AlphaPYPD
      PolyPid Ltd. (PYPD) Analyst/Investor Day - Slideshow (NASDAQ:PYPD) 2026-11-01

      2026-11-01. The following slide deck was published by PolyPid Ltd.

      Nov 1Seeking AlphaPYPD
      PolyPid to Report Third Quarter 2026 Financial Results and Operational Highlights on November 11, 2026
      Oct 29Yahoo FinancePYPD
      PolyPid Targets 2027 D-PLEX100 Launch, Unveils Diabetic Foot Infection Program
      Oct 29Yahoo FinancePYPD
      PolyPid unveils PD01B for diabetic foot infection treatment
      Oct 28Investing.comPYPD
      PolyPid Unveils Expanded Pipeline Strategy, Introducing PD01B, a New Kynatrix™ Based Product Candidate for the Treatment of Diabetic Foot Infections
      Oct 28Yahoo FinancePYPD
      PolyPid stock gains new Outperform at Oppenheimer (PYPD:NASDAQ)
      Oct 27Seeking AlphaPYPDOPY
      Oppenheimer initiates PolyPid stock coverage with outperform rating
      Oct 27Investing.comPYPD
      PolyPid to Present D-PLEX₁₀₀ Microbiology Data at IDWeek 2026
      Oct 21Yahoo FinancePYPD
      PolyPid to Host Virtual Investor Day on Wednesday, October 28, 2026
      Oct 15Yahoo FinancePYPD
      What PolyPid’s Bold Moves in Europe Could Mean for D-PLEX₁₀₀’s Global Potential (NASDAQ: PYPD)

      Detailed price information for Polypid Ltd (PYPD-Q) from The Globe and Mail including charting and trades.

      Oct 10The Globe and MailPYPD
      What PolyPid's Bold Moves in Europe Could Mean for D-PLEX₁₀₀'s Global Potential (NASDAQ: PYPD) - PolyPid

      WSW, NY, October 9th, 2026, FinanceWireTwo announcements on the same day put a validated European application and full European commercial rights in PolyPid's hands, and may point to value well beyond the U.S. deal

      Oct 9BenzingaPYPD
      What PolyPid’s Bold Moves in Europe Could Mean for D-PLEX₁₀₀’s Global Potential (NASDAQ: PYPD)

      Tipranks Press Release.

      Oct 9The Globe and MailPYPD
      PolyPid Nears FDA Decision for D-PLEX100 After Strong Phase III Data

      PolyPid (NASDAQ:PYPD) is approaching a November 28 PDUFA date for D-PLEX100, its lead product candidate for preventing surgical site infections in patients undergoing colorectal surgery, Chief Executive Officer Dikla Czaczkes Akselbrad said during the Lytham Partners Fall 2026 Investor Conference.

      Oct 4Yahoo FinancePYPD
      PolyPid receives EMA validation for D-PLEX100 application
      Oct 1Investing.comPYPD
      PolyPid regains European rights for D-PLEX after deal ends
      Oct 1Investing.comPYPD
      European Medicines Agency Validates PolyPid’s Marketing Authorization Application for D-PLEX₁₀₀
      Oct 1Yahoo FinancePYPD
      PolyPid Regains European Commercialization Rights for D-PLEX₁₀₀, Expanding Global Commercialization Opportunities
      Oct 1Yahoo FinancePYPD
      PolyPid at Lytham Partners: FDA decision nears for lead drug
      Sep 29Investing.comPYPD
      PolyPid Announces Participation in Upcoming Fall Investor Conferences

      PETACH TIKVA, Israel, Sept. 15, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that senior management will participate in the following upcoming investor conferences: 5th Annual ROTH Healthcare Opportunities ConferenceDates: September 29, 2026Location: Metropolitan Club, New York, NYFormat: Panel discuss

      Sep 15Yahoo FinancePYPD

      This is the newest page. Registered accounts read further back.